PCPaola Caprino

Paola Caprino

*This is an algorithmically generated author record based on publicly available information.

Paola Caprino has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis

    by G. Pellino, M. Carvello, V. Celentano, C. Coco, F. Colombo, A. Geccherle, G. Luglio, M. Rottoli, M. Scarpa, G. Sciaudone, et al.

    The Italian Society of Colorectal Surgery (SICCR) promoted the project reported here, which consists of a Position Statement of Italian colorectal surgeons to address the surgical aspects of ulcerative colitis management. Members of the society were invited to express their opinions on several items proposed by the writing committee, based on evidence available in the literature. The results are presented, focusing on relevant points. The present paper is not an alternative to available guidelines; rather, it offers a snapshot of the attitudes of SICCR surgeons about the surgical treatment of ulcerative colitis. The committee was able to identify some points of major disagreement and suggested strategies to improve the quality of available data and acceptance of guidelines.


  • Total Colon “Collapse” in Giant Left-Sided Inguino-Scrotal Hernia: Double-Mesh Plastic Repair

    by Paola Caprino, Franco Sacchetti, Carlo Alberto Schena, Luigi Sofo

  • Open Access

    Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: A narrative review

    by Luigi Sofo, Paola Caprino, Franco Sacchetti, Maurizio Bossola

    Restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: A narrative review


    • 1 June 2012
      • Vol. 16  (6) , 737-42

    Complications related to hyperthermia during hypertermic intraoperative intraperitoneal chemiotherapy (HIPEC) treatment. Do they exist?

    by D Di Miceli, S Alfieri, Paola Caprino, R Menghi, Giuseppe Quero, C Cina, M Pericoli Ridolfini, G B Doglietto

    Hyperthermia, either alone or in combination with anticancer drugs, is becoming more and more a clinical reality for the treatment of far advanced gastrointestinal cancers, acting as a cytotoxic agent at a temperature between 40-42.5 degrees C. Although hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) is demonstrated to have some benefit in selected patients with peritoneal seeding, there are not enough data on the risk of damage of normal tissue that increases as the temperature rises, with possible serious and, sometimes, lethal complications. We searched on medline words like "intraoperative intraperitoneal chemohyperthermia and morbidity", focusing our attention on studies (published since 1990) which reported morbidity as bowel obstruction, bowel perforation or anastomic leak, during intraoperative intraoperitoneal chemotherapy in hyperthermia (HIPEC). Heat acts increasing cancer cell killing after exposure to ionizing radiation, inhibiting repairing processes of radiation-induced DNA lesions (radiosensitization), and also sensitizing cancer cells to chemotherapeutic drugs, particularly to alkylating agents (chemosensitization). The peritoneal carcinomatosis (a frequent evolution of advanced digestive cancer) represents one of the main indication to hypertermic treatment. In the last fifteen years, in fact, different methods were developed for the surgery treatment (peritonectomy) and for loco-regional chemotherapic treatment of the carcinomatosis (intraperitoneal intra/post-operative iper/normothermic chemotherapy) to act directly on neoplastic seeding. We found, as result of different studies, 9 articles, written about perforation after HIPEC. The aim of the present study is to present the review of the literature in terms of peri-operative complications related to the hyperthermia during intraoperative chemohyperthermia procedure.


    • 23 February 2012
      • Vol. 83  (1) , 71-3

    A very advanced case of a T cell peritoneal lymphomatosis.

    by Marco Pericoli Ridolfini, Paola Caprino, Stefano Berardi, Fabio Rotondi, Giacomo Cusumano, Luigi Sofo, Fabio Pacelli, Giovanni Battista Doglietto

    Small-bowel lymphoma is not a common disease, accounting for 15-20% of primary extranodal gastrointestinal lymphomas. Peritoneal lymphomatosis is considered a rare and aggressive presentation. We describe the case of a 55 years-old man affected by T-cell intestinal lymphoma, presenting with diffuse abdominal involvement, bowel dysfunction, severe ascites and pleural effusion, who underwent surgery. Clinical course led dramatically to death. Preoperative cytology and radiologic investigations did not yield diagnosis and were unable to differentiate between peritoneal carcinosis and lymphomatosis. It is suggested that, in such advanced cases, with rapidly deteriorating clinical conditions and huge systemic involvement, surgery is not indicated. On the contrary, maximum effort has to be spent to obtain a preoperative diagnosis.


  • Open Access

    Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study

    by Alessio G. Morganti, Vincenzo Picardi, Edy Ippolito, Mariangela Massaccesi, Gabriella Macchia, Francesco Deodato, Gian Carlo Mattiucci, Luciana Caravatta, Liberato Di Lullo, Gianfranco Giglio, et al.

    The objective of this study was to evaluate the safety of escalating up to 55 Gy within five weeks, the dose of external beam radiotherapy to the previous tumor site concurrently with a fixed daily dose of capecitabine, in patients with resected pancreatic cancer. Material and methods. Patients with resected pancreatic carcinoma were eligible for this study. Capecitabine was administered at a daily dose of 1600 mg/m 2. Regional lymph nodes received a total radiation dose of 45 Gy with 1.8 Gy per fractions. The starting radiation dose to the tumor bed was 50.0 Gy (2.0 Gy/fraction, 25 fractions). Escalation was achieved up to a total dose of 55.0 Gy by increasing the fraction size by 0.2 Gy (2.2 Gy/fraction), while keeping the duration of radiotherapy to five weeks (25 fractions). A concomitant boost technique was used. Dose limiting toxicity (DLT) was defined as any grade>3 hematologic toxicity, grade>2 liver, renal, neurologic, gastrointestinal, or skin toxicity, by RTOG criteria, or any toxicity producing prolonged (> 10 days) radiotherapy interruption. Results and discussion. Twelve patients entered the study (median age: 64 years). In the first cohort (six patients), no patient experienced DLT. Similarly in the second cohort, no DLT occurred. All 12 patients completed the planned regimen of therapy. Nine patients experienced grade 1-2 nausea and/or vomiting. Grade 2 hematological toxicity occurred in four patients. The results of our study indicate that a total radiation dose up to 55.0 Gy/5 weeks can be safely administered to the tumor bed, concurrently with capecitabine (1600 mg/m 2) in patients with resected pancreatic carcinoma.


  • Image of the Month—Quiz Case

    by Paola Caprino, Marco Pericoli Ridolfini, Stefano Berardi, Luigi Sofo, Domenico D’ugo

    Case Report from JAMA Surgery — Image of the Month—Quiz Case

    • 8 October 2008
      • Vol. 60  (4) , 493-508

    [Cystic tumors of the pancreas: diagnosis, management and results].

    by Sergio Alfieri, Marco Pericoli Ridolfini, Claudio Bassi, Stavros Gourgiotis, Paola Caprino, Paolo Pederzoli, Luigi Sofo, Giovanni Battista Doglietto

    Pancreatic cystic tumours are rare and less frequent than other pancreatic tumours. In recent decades, these tumours are being diagnosed with increasing frequency due to the extensive availability of, and improvement in, modern imaging techniques and it is often possible not only to differentiate them preoperatively from other cystic pancreatic disorders but also from one another. Pancreatic cystic tumours comprise a variety of neoplasms with a wide range of malignant potential: serous cystic tumours are benign, whereas mucinous cystic tumours, and intraductal papillary mucinous tumours are considered premalignant, while solid pseudopapillary tumours have a non-aggressive behaviour in the vast majority of cases. Most patients have no symptoms; and when clinical signs are present, they never help us to identify the type of pathology. Serous cystic neoplasms usually do not mandate resection unless the lesion is symptomatic. Mucinous cystic neoplasms and intraductal papillary mucinous neoplasms have a premalignant or malignant tendency, and therefore need to be managed aggressively by pancreatic resection. Their prognosis is excellent in the absence of invasive disease, but the presence of invasive malignancy is associated with a poor prognosis. This review addresses the symptoms, diagnosis, management and prognosis of this group of tumours.